- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Multiple sclerosis (MS)
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 399KB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 78KB)
Fingolimod ofatumumab siponimod – November 2024
Fingolimod, Ofatumumab, Siponimod: Fingolimod; Capsule 250 micrograms (as hydrochloride) Capsule 500 micrograms (as hydrochloride); Gilenya®; Ofatumumab; Solution for injection 20 mg in 0.4 mL pre filled pen; Kesimpta®; Siponimod; Tablet 250 micrograms (as hemifumarate) Tablet 2 mg (as hemifumarate); Mayzent®
Last updated
30 May 2025
